Trojan, A; Tinguely, M; Vallet, S; Seifert, Burkhardt; Jenni, B; Zippelius, A; Witzens-Harig, M; Mechtersheimer, G; Ho, A; Goldschmidt, H; Jäger, D; Boccadoro, M; Ladetto, M (2006). Clinical significance of cyclooxygenase-2 (COX-2) in multiple myeloma. Swiss Medical Weekly, 136(25-26):400-403.
View at publisher
Several biological and clinical considerations suggest the involvement of cyclooxygenase-2 (COX-2), the key enzyme of prostaglandin (PG) synthesis, in the pathogenesis and progression of haematological malignancies. Despite the wealth of data concerning COX-2 expression, only limited information is available on multiple myeloma (MM). Using standard immunohistochemistry we therefore evaluated COX-2 protein expression in samples from 57 patients with a primary diagnosis of MM. Time to progression and a variety of clinicopathological features were evaluated by the Kaplan-Meier method and the Cox regression model. In addition, COX-2 expression was evaluated by staining bone marrow from healthy donors and 11 patients with MGUS. Overall, 31 MM samples (54%) expressed COX-2. Positivity for COX-2 was unrelated to stage or clinical or molecular features of the disease. However, patients with COX-2 positive tumours experienced a significantly shorter time to progression (17 vs 30 months, p = 0.037). In summary, COX-2 is frequently expressed in MM and correlates with shorter progression-free survival.
64 downloads since deposited on 20 May 2009
18 downloads since 12 months
|Item Type:||Journal Article, refereed, original work|
|Communities & Collections:||04 Faculty of Medicine > Epidemiology, Biostatistics and Prevention Institute (EBPI)|
|Dewey Decimal Classification:||610 Medicine & health|
|Deposited On:||20 May 2009 07:25|
|Last Modified:||02 Jun 2015 07:26|
|Publisher:||EMH Swiss Medical Publishers|
Users (please log in): suggest update or correction for this item
Repository Staff Only: item control page